Raymond James Highlights Viking’s New Amylin-Based Weight Loss Drug VK3019 Entering Clinic

Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.